Dupixent wins FDA OK for asthma; Seres poaches new CMO from AstraZeneca

Sanofi and Regeneron won FDA approval to market Dupixent for asthma. “Dupixent is now approved in the U.S. for two important groups of uncontrolled asthma patients – those who are moderate-to-severe with an eosinophilic phenotype or those with oral corticosteroid-dependent asthma,” said George Yancopoulos, president and CSO of Regeneron.

AstraZeneca vet Kevin Horgan is jumping over to Cambridge, MA-based Seres as its new CMO. “Kevin is an accomplished drug developer with extensive experience successfully leading numerous mid- and late-stage clinical programs to approval. Seres’ R&D efforts are increasingly focused on early and later stage immunological indications, and Kevin’s deep clinical background in these areas makes him very well suited to lead our clinical development studies,” said Seres CEO Roger Pomerantz.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->